Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 411

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Marzia Palma, MD PhD, Tom A. Mulder, MD, Kia Heimersson, Li-Sophie Rathje, PhD, Thomas Olin, MSc,PhD, Johan Schultz, MSc,PhD, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD

Blood (2019) 134 (Supplement_1): 5445.

https://doi.org/10.1182/blood-2019-121818

Published: 2019

Journal Articles

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Blood (2019) 134 (Supplement_1): 5275.

https://doi.org/10.1182/blood-2019-129295

Published: 2019

Journal Articles

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

Juan J delMoral-Diez, MD, Elena Juventina Tuna-Aguilar, MD, Alvaro Aguayo, MD, Antonio Olivas-Martinez, MD, Gladys P Agreda-Vasquez, MD

Blood (2019) 134 (Supplement_1): 5281.

https://doi.org/10.1182/blood-2019-123792

Published: 2019

Journal Articles

BCL2 Expression Correlates with Refractory and Relapsed Classic Hodgkin Lymphoma. Its Blokeadge As a Promising Directed-Therapy

Angelica Gamboa-Cedeño, Cristaldo Nancy, MD, Victoria Otero, MD, Natalia Paola Schutz, MDMSc, Dorotea Fantl, MD, Maria Silvana Cugliari, Marta Zerga, MD, Rojas-Bilbao Erica, Hernán García Rivello, Federico Jauk, MD, Myriam Nuñez, PhD, Stella Maris Ranuncolo, MD PhD

Blood (2019) 134 (Supplement_1): 5282.

https://doi.org/10.1182/blood-2019-124452

Published: 2019

Journal Articles

Time to Change Our Practice: Experience in the Treatment of Steroid Refractory Graft Versus Host Disease in a Universitary Hospital in Chile

Nicolas Triantafilo, MD, Mauricio Sarmiento Maldonado, MD, Felipe Palacios, MD, James Campbell, MD, Vicente Sandoval, MD, Andres Rojas, MD, Jara Veronica, Soto Katherine, Silvana Arellano, Carla Lorca, Isabel Pizarro, Elizabeth Rivera, Mauricio Galleguillos, Isabel Rodriguez, Pablo Bertin, MD, Mauricio Ocqueteau, MD, Jaime Pereira, MD

Blood (2019) 134 (Supplement_1): 5683.

https://doi.org/10.1182/blood-2019-131737

Published: 2019

Journal Articles

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Carlos García, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brener Sabando, MD, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Kenny Galvez, MD, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Raimundo Gazitua, MD, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Macarena Roa, MD, Eloisa Riva, MD

Blood (2019) 134 (Supplement_1): 5497.

https://doi.org/10.1182/blood-2019-127555

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

https://doi.org/10.1182/blood-2019-125495

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Luis E Malpica Castillo, MD, Camila Peña, MD, Christine Rojas, MD, Pilar León, MD, Brady E. Beltrán, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Mimsy Quinones, MD, Sally Rose Paredes, MD, Henry Idrobo, MD, Ivan Perdomo, MD, Virginia Abello, MD, Lorena Fiad, MD, Victoria Otero, MD, Marialejandra Torres Viera, MD, Luis Villela M, Eduardo Sotomayor, MD, Jorge J Castillo, MD, Juan Carlos Ramos, MD BS

Blood (2019) 134 (Supplement_1): 4045.

https://doi.org/10.1182/blood-2019-122976

Published: 2019

Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS

Blood (2019) 134 (Supplement_1): 4054.

https://doi.org/10.1182/blood-2019-121523

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Immune escape mechanisms for TCRLBCL

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

BCL2 Expression Correlates with Refractory and Relapsed Classic Hodgkin Lymphoma. Its Blokeadge As a Promising Directed-Therapy

Time to Change Our Practice: Experience in the Treatment of Steroid Refractory Graft Versus Host Disease in a Universitary Hospital in Chile

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only